ARQT PE Ratio & Valuation,Is ARQT Overvalued

ARQT Relative Valuation

ARQT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARQT is overvalued; if below, it's undervalued.

Historical Valuation

Arcutis Biotherapeutics Inc (ARQT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.08 is considered Undervalued compared with the five-year average of -8.35. The fair price of Arcutis Biotherapeutics Inc (ARQT) is between 713.23 to 718.97 according to relative valuation methord. Compared to the current price of 29.03 USD , Arcutis Biotherapeutics Inc is Undervalued By 95.93%.

Relative Value

Fair Zone

713.23-718.97

Current Price：29.03

95.93%

Undervalued

76.54

36.21

EV/EBITDA

Arcutis Biotherapeutics Inc. (ARQT) has a current EV/EBITDA of 36.21. The 5-year average EV/EBITDA is -11.24. The thresholds are as follows: Strongly Undervalued below -80.93, Undervalued between -80.93 and -46.09, Fairly Valued between 23.60 and -46.09, Overvalued between 23.60 and 58.44, and Strongly Overvalued above 58.44. The current Forward EV/EBITDA of 36.21 falls within the Overvalued range.

65.35

EV/EBIT

Arcutis Biotherapeutics Inc. (ARQT) has a current EV/EBIT of 65.35. The 5-year average EV/EBIT is -12.22. The thresholds are as follows: Strongly Undervalued below -97.52, Undervalued between -97.52 and -54.87, Fairly Valued between 30.43 and -54.87, Overvalued between 30.43 and 73.09, and Strongly Overvalued above 73.09. The current Forward EV/EBIT of 65.35 falls within the Overvalued range.

8.08

Arcutis Biotherapeutics Inc. (ARQT) has a current PS of 8.08. The 5-year average PS is 102.06. The thresholds are as follows: Strongly Undervalued below -253.01, Undervalued between -253.01 and -75.47, Fairly Valued between 279.60 and -75.47, Overvalued between 279.60 and 457.13, and Strongly Overvalued above 457.13. The current Forward PS of 8.08 falls within the Historic Trend Line -Fairly Valued range.

71.38

P/OCF

Arcutis Biotherapeutics Inc. (ARQT) has a current P/OCF of 71.38. The 5-year average P/OCF is -1.87. The thresholds are as follows: Strongly Undervalued below -49.21, Undervalued between -49.21 and -25.54, Fairly Valued between 21.79 and -25.54, Overvalued between 21.79 and 45.46, and Strongly Overvalued above 45.46. The current Forward P/OCF of 71.38 falls within the Strongly Overvalued range.

48.04

P/FCF

Arcutis Biotherapeutics Inc. (ARQT) has a current P/FCF of 48.04. The 5-year average P/FCF is 6.94. The thresholds are as follows: Strongly Undervalued below -62.91, Undervalued between -62.91 and -27.98, Fairly Valued between 41.86 and -27.98, Overvalued between 41.86 and 76.78, and Strongly Overvalued above 76.78. The current Forward P/FCF of 48.04 falls within the Overvalued range.

Arcutis Biotherapeutics Inc (ARQT) has a current Price-to-Book (P/B) ratio of 22.08. Compared to its 3-year average P/B ratio of 8.15 , the current P/B ratio is approximately 170.73% higher. Relative to its 5-year average P/B ratio of 6.43, the current P/B ratio is about 243.57% higher. Arcutis Biotherapeutics Inc (ARQT) has a Forward Free Cash Flow (FCF) yield of approximately -0.94%. Compared to its 3-year average FCF yield of -30.43%, the current FCF yield is approximately -96.93% lower. Relative to its 5-year average FCF yield of -24.27% , the current FCF yield is about -96.15% lower.

22.08

P/B

Median3y

8.15

Median5y

6.43

-0.94

FCF Yield

Median3y

-30.43

Median5y

-24.27

Competitors Valuation Multiple

The average P/S ratio for ARQT's competitors is 847.05, providing a benchmark for relative valuation. Arcutis Biotherapeutics Inc Corp (ARQT) exhibits a P/S ratio of 8.08, which is -99.05% above the industry average. Given its robust revenue growth of 121.69%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ARQT increased by 108.33% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 44.76M to 99.22M.

The secondary factor is the P/E Change, contributed 94.69%to the performance.

Overall, the performance of ARQT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

121.69%

44.76M → 99.22M

Revenue Growth

-108.05%

-92.81 → 7.47

Margin Expansion

94.69%

-42.49 → -82.73

P/E Change

108.33%

13.93 → 29.02

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Arcutis Biotherapeutics Inc (ARQT) currently overvalued or undervalued?

What is Arcutis Biotherapeutics Inc (ARQT) fair value?

ARQT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Arcutis Biotherapeutics Inc (ARQT) is between 713.23 to 718.97 according to relative valuation methord.

How does ARQT's valuation metrics compare to the industry average?

What is the current P/B ratio for Arcutis Biotherapeutics Inc (ARQT) as of Dec 15 2025?

As of Dec 15 2025, Arcutis Biotherapeutics Inc (ARQT) has a P/B ratio of 22.08. This indicates that the market values ARQT at 22.08 times its book value.

What is the current FCF Yield for Arcutis Biotherapeutics Inc (ARQT) as of Dec 15 2025?

As of Dec 15 2025, Arcutis Biotherapeutics Inc (ARQT) has a FCF Yield of -0.94%. This means that for every dollar of Arcutis Biotherapeutics Inc’s market capitalization, the company generates -0.94 cents in free cash flow.

What is the current Forward P/E ratio for Arcutis Biotherapeutics Inc (ARQT) as of Dec 15 2025?

As of Dec 15 2025, Arcutis Biotherapeutics Inc (ARQT) has a Forward P/E ratio of 76.54. This means the market is willing to pay $76.54 for every dollar of Arcutis Biotherapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Arcutis Biotherapeutics Inc (ARQT) as of Dec 15 2025?

As of Dec 15 2025, Arcutis Biotherapeutics Inc (ARQT) has a Forward P/S ratio of 8.08. This means the market is valuing ARQT at $8.08 for every dollar of expected revenue over the next 12 months.

ARQT Valuation